Do Options Traders Know Something About Savara (SVRA) Stock We Don't?Zacks Investment Research • 03/18/21
Savara Announces Closing of $130 Million Public Offering Following Full Exercise of Underwriters' OptionBusiness Wire • 03/15/21
Savara Announces Participation in Fireside Chats at Two Upcoming Virtual Investor Healthcare ConferencesBusiness Wire • 11/24/20
Savara's IMPALA 2 Trial Seems Well-Tailored To Get Positive Phase 3 Data For MolgradexSeeking Alpha • 11/24/20
Savara Reports Third Quarter 2020 Financial Results and Provides Business UpdateBusiness Wire • 11/05/20
Savara to Present at the 22nd Annual H.C. Wainwright Annual Investment Conference Being Held VirtuallyBusiness Wire • 09/09/20
Savara Announces New England Journal of Medicine (NEJM) Publication of IMPALA Study ResultsBusiness Wire • 09/08/20
Savara to Discontinue Exploratory ENCORE Study Evaluating Molgradex for the Treatment of NTM Lung Infection in People Living With Cystic Fibrosis (CF)Business Wire • 09/03/20
Savara Inc (SVRA) CEO Robert Neville on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/07/20
Savara Reports Second Quarter 2020 Financial Results and Provides Business UpdateBusiness Wire • 08/06/20
Savara to Present at the 40th Annual Canaccord Genuity Global Growth Conference to be Held VirtuallyBusiness Wire • 08/05/20
Savara to Report Second Quarter 2020 Financial Results and Provide Business UpdateBusiness Wire • 07/30/20
Savara Inc. (SVRA) CEO Rob Neville on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/07/20